Amended Current Report Filing (8-k/a)
May 16 2022 - 04:19PM
Edgar (US Regulatory)
0001821586 true 00-0000000 CH 0001821586
2022-04-05 2022-04-05 iso4217:USD xbrli:shares iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
Amendment
No. 1
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): May 13, 2022
(April
5, 2022)
MOONLAKE IMMUNOTHERAPEUTICS
(Exact
name of registrant as specified in its charter)
Cayman Islands |
|
001-39630 |
|
N/A |
(State
or other jurisdiction |
|
(Commission
File Number) |
|
(I.R.S.
Employer |
of
incorporation) |
|
|
|
Identification
No.) |
Dorfstrasse 29 |
|
|
Zug, Switzerland |
|
6300 |
(Address
of principal executive offices) |
|
(Zip
Code) |
41
415108022
(Registrant’s
telephone number, including area code)
Helix
Acquisition Corp.
Cormorant
Asset Management, LP
200
Clarendon Street, 52nd Floor
Boston,
MA
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ |
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
☐ |
Pre-commencements
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Securities Exchange Act
of 1934:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Class A ordinary share, par value $0.0001 per
share |
|
MLTX |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company ☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
INTRODUCTORY
NOTE
This
Amendment No. 1 on Form 8-K/A (“Amendment No. 1”) amends the
Current Report on Form 8-K of MoonLake Immunotherapeutics, a Cayman
Islands exempted company (formerly known as Helix Acquisition
Corp.) (prior to the Closing Date, “Helix” and after the Closing
Date, “MoonLake”), filed on April 11, 2022 (the “Original Report”),
in which the Company (as defined below) reported, among other
events, the closing of the Business Combination (as defined in the
Original Report) on April 5, 2022 (the “Closing Date”).
In connection with the closing of the Business Combination, the
registrant changed its name from Helix Acquisition Corp. to
MoonLake Immunotherapeutics. Unless the context otherwise requires,
“MoonLake,” “we,” “us,” “our,” and the “Company” refer to the
combined company following the Business Combination, together with
its subsidiaries, “Helix” refers to the registrant prior to the
closing of the Business Combination and “MoonLake AG” refers to
MoonLake Immunotherapeutics AG, a Swiss stock corporation
(Aktiengesellschaft) registered with the commercial register of the
Canton of Zug, Switzerland under the number CHE-433.093.536,
together with its subsidiaries, prior to the Business
Combination.
This Amendment No. 1 includes (i) the unaudited condensed
consolidated financial statements of MoonLake AG as of and for the
three months ended March 31, 2022, (ii) MoonLake AG’s Management’s
Discussion and Analysis of Financial Condition and Results of
Operations for the three months ended March 31, 2022, and (iii) the
unaudited pro forma condensed combined balance sheet as of March
31, 2022 and the unaudited pro forma condensed combined statement
of operations for the three months ended March 31, 2022 and the
year ended December 31, 2021.
This Amendment No. 1 does not amend any other item of the Original
Report or purport to provide an update or a discussion of any
developments at the Company or its subsidiaries, including MoonLake
AG, subsequent to the filing date of the Original Report. The
information previously reported in or filed with the Original
Report is hereby incorporated by reference to this Form
8-K/A.
Item
2.01. Results of Operations and Financial Condition.
This
Amendment No. 1 includes (i) the unaudited condensed consolidated
financial statements of MoonLake AG as of and for the three months
ended March 31, 2022, (ii) MoonLake AG’s Management’s Discussion
and Analysis of Financial Condition and Results of Operations for
the three months ended March 31, 2022, and (iii) the unaudited pro
forma condensed combined balance sheet as of March 31, 2022 and the
unaudited pro forma condensed combined statement of operations for
the three months ended March 31, 2022 and the year ended December
31, 2021.
The
information set forth under Item 9.01 of this Current Report on
Form 8-K is incorporated herein by reference.
Item
9.01 Exhibits.
(a)
Financial Statements of Business Acquired
The
unaudited condensed consolidated financial statements of MoonLake
AG as of and for the three months ended March 31, 2022, and the
related notes thereto are attached as Exhibit 99.1 and are
incorporated herein by reference. Also included as Exhibit 99.2 and
incorporated herein by reference is MoonLake AG’s Management’s
Discussion and Analysis of Financial Condition and Results of
Operations for the three months ended March 31, 2022.
(b)
Pro Forma Financial Information
The
unaudited pro forma condensed combined balance sheet as of March
31, 2022 and the unaudited pro forma condensed combined statement
of operations for the three months ended March 31, 2022 and the
year ended December 31, 2021, and the related notes thereto are
attached as Exhibit 99.3 and are incorporated herein by
reference.
(d)
Exhibits
EXHIBIT
INDEX
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
MoonLake
Immunotherapeutics |
|
|
Date:
May 16, 2022 |
By: |
/s/
Matthias Bodenstedt |
|
Name: |
Matthias
Bodenstedt |
|
Title: |
Chief
Financial Officer |
3
MoonLake Immunotherapeut... (NASDAQ:MLTX)
Historical Stock Chart
From Jul 2022 to Aug 2022
MoonLake Immunotherapeut... (NASDAQ:MLTX)
Historical Stock Chart
From Aug 2021 to Aug 2022